Cargando…
Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide, with fibrosis stage being the main predictor for clinical outcomes. Here, we present the metabolic profile of NAFLD patients with regards to fibrosis progression. We included all consecutive new referrals...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961068/ https://www.ncbi.nlm.nih.gov/pubmed/36834973 http://dx.doi.org/10.3390/ijms24043563 |
_version_ | 1784895663991947264 |
---|---|
author | Jambulingam, Nila Forlano, Roberta Preston, Benjamin Mullish, Benjamin H. Portone, Greta Baheer, Yama Yee, Michael Goldin, Robert D. Thursz, Mark R. Manousou, Pinelopi |
author_facet | Jambulingam, Nila Forlano, Roberta Preston, Benjamin Mullish, Benjamin H. Portone, Greta Baheer, Yama Yee, Michael Goldin, Robert D. Thursz, Mark R. Manousou, Pinelopi |
author_sort | Jambulingam, Nila |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide, with fibrosis stage being the main predictor for clinical outcomes. Here, we present the metabolic profile of NAFLD patients with regards to fibrosis progression. We included all consecutive new referrals for NAFLD services between 2011 and 2019. Demographic, anthropometric and clinical features and noninvasive markers of fibrosis were recorded at baseline and at follow-up. Significant and advanced fibrosis were defined using liver stiffness measurement (LSM) as LSM ≥ 8.1 kPa and LSM ≥ 12.1 kPa, respectively. Cirrhosis was diagnosed either histologically or clinically. Fast progressors of fibrosis were defined as those with delta stiffness ≥ 1.03 kPa/year (25% upper quartile of delta stiffness distribution). Targeted and untargeted metabolic profiles were analysed on fasting serum samples using Proton nuclear magnetic resonance ((1)H NMR). A total of 189 patients were included in the study; 111 (58.7%) underwent liver biopsy. Overall, 11.1% patients were diagnosed with cirrhosis, while 23.8% were classified as fast progressors. A combination of metabolites and lipoproteins could identify the fast fibrosis progressors (AUROC 0.788, 95% CI: 0.703–0.874, p < 0.001) and performed better than noninvasive markers. Specific metabolic profiles predict fibrosis progression in patients with nonalcoholic fatty liver disease. Algorithms combining metabolites and lipids could be integrated in the risk-stratification of these patients. |
format | Online Article Text |
id | pubmed-9961068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99610682023-02-26 Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease Jambulingam, Nila Forlano, Roberta Preston, Benjamin Mullish, Benjamin H. Portone, Greta Baheer, Yama Yee, Michael Goldin, Robert D. Thursz, Mark R. Manousou, Pinelopi Int J Mol Sci Article Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide, with fibrosis stage being the main predictor for clinical outcomes. Here, we present the metabolic profile of NAFLD patients with regards to fibrosis progression. We included all consecutive new referrals for NAFLD services between 2011 and 2019. Demographic, anthropometric and clinical features and noninvasive markers of fibrosis were recorded at baseline and at follow-up. Significant and advanced fibrosis were defined using liver stiffness measurement (LSM) as LSM ≥ 8.1 kPa and LSM ≥ 12.1 kPa, respectively. Cirrhosis was diagnosed either histologically or clinically. Fast progressors of fibrosis were defined as those with delta stiffness ≥ 1.03 kPa/year (25% upper quartile of delta stiffness distribution). Targeted and untargeted metabolic profiles were analysed on fasting serum samples using Proton nuclear magnetic resonance ((1)H NMR). A total of 189 patients were included in the study; 111 (58.7%) underwent liver biopsy. Overall, 11.1% patients were diagnosed with cirrhosis, while 23.8% were classified as fast progressors. A combination of metabolites and lipoproteins could identify the fast fibrosis progressors (AUROC 0.788, 95% CI: 0.703–0.874, p < 0.001) and performed better than noninvasive markers. Specific metabolic profiles predict fibrosis progression in patients with nonalcoholic fatty liver disease. Algorithms combining metabolites and lipids could be integrated in the risk-stratification of these patients. MDPI 2023-02-10 /pmc/articles/PMC9961068/ /pubmed/36834973 http://dx.doi.org/10.3390/ijms24043563 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jambulingam, Nila Forlano, Roberta Preston, Benjamin Mullish, Benjamin H. Portone, Greta Baheer, Yama Yee, Michael Goldin, Robert D. Thursz, Mark R. Manousou, Pinelopi Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease |
title | Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease |
title_full | Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease |
title_fullStr | Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease |
title_full_unstemmed | Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease |
title_short | Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease |
title_sort | metabolic profile reflects stages of fibrosis in patients with non-alcoholic fatty liver disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961068/ https://www.ncbi.nlm.nih.gov/pubmed/36834973 http://dx.doi.org/10.3390/ijms24043563 |
work_keys_str_mv | AT jambulingamnila metabolicprofilereflectsstagesoffibrosisinpatientswithnonalcoholicfattyliverdisease AT forlanoroberta metabolicprofilereflectsstagesoffibrosisinpatientswithnonalcoholicfattyliverdisease AT prestonbenjamin metabolicprofilereflectsstagesoffibrosisinpatientswithnonalcoholicfattyliverdisease AT mullishbenjaminh metabolicprofilereflectsstagesoffibrosisinpatientswithnonalcoholicfattyliverdisease AT portonegreta metabolicprofilereflectsstagesoffibrosisinpatientswithnonalcoholicfattyliverdisease AT baheeryama metabolicprofilereflectsstagesoffibrosisinpatientswithnonalcoholicfattyliverdisease AT yeemichael metabolicprofilereflectsstagesoffibrosisinpatientswithnonalcoholicfattyliverdisease AT goldinrobertd metabolicprofilereflectsstagesoffibrosisinpatientswithnonalcoholicfattyliverdisease AT thurszmarkr metabolicprofilereflectsstagesoffibrosisinpatientswithnonalcoholicfattyliverdisease AT manousoupinelopi metabolicprofilereflectsstagesoffibrosisinpatientswithnonalcoholicfattyliverdisease |